Theratechnologies Inc
TSX:TH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Komori Corp
TSE:6349
|
JP |
|
I
|
Idun Industrier AB (publ)
STO:IDUN B
|
SE |
|
S
|
Shizuki Electric Co Inc
TSE:6994
|
JP |
|
AgroGalaxy Participacoes SA
BOVESPA:AGXY3
|
BR |
|
P
|
Power and Water Utility Company for Jubail and Yanbu
SAU:2083
|
SA |
|
Furuno Electric Co Ltd
TSE:6814
|
JP |
|
J
|
Jinzai Food Group Co Ltd
SZSE:003000
|
CN |
Theratechnologies Inc
Total Assets
Theratechnologies Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theratechnologies Inc
TSX:TH
|
Total Assets
$51.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
5%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Assets
CA$84.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Assets
$751.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
36%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Assets
$633.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
26%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Assets
CA$86.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Assets
$221.5m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
Glance View
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
See Also
What is Theratechnologies Inc's Total Assets?
Total Assets
51.3m
USD
Based on the financial report for May 31, 2025, Theratechnologies Inc's Total Assets amounts to 51.3m USD.
What is Theratechnologies Inc's Total Assets growth rate?
Total Assets CAGR 10Y
5%
Over the last year, the Total Assets growth was -27%. The average annual Total Assets growth rates for Theratechnologies Inc have been -19% over the past three years , -14% over the past five years , and 5% over the past ten years .
